InsiderSignal.AI

InsiderSignal.ai

LRMR - Larimar Therapeutics, Inc.

Insider Purchase by Flynn James E (* Director by Deputization, 10%)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Flynn James E, serving as * Director by Deputization, 10% owner at Larimar Therapeutics, Inc. (LRMR), purchased 9,375,000 shares at $3.20 per share, for a total transaction value of $30,000,000.00. Following this transaction, Flynn James E now holds 30,606,974 shares of LRMR.

This purchase represents a 44.00% increase in Flynn James E's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, July 31, 2025 and publicly disclosed via SEC Form 4 filing on Monday, August 4, 2025, 4 days after the trade was made.

Larimar Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Flynn James E

* Director by Deputization, 10%

James E. Flynn is the Managing Partner of Deerfield Management, a leading healthcare-focused investment firm, where he joined in 2000 and assumed leadership in 2005.[[1]](https://biofuture.com/james-e-flynn/)[[2]](https://www.leadersmag.com/issues/2022.3_Jul/Purpose/LEADERS_James_Flynn_Deerfield.html)[[3]](https://fintool.com/app/research/funds/hedge-funds/deerfield-management-company-lp-series-c/people/james-flynn) Under his direction, Deerfield has expanded into healthcare information via the Deerfield Institute, venture investments, Deerfield Discovery and Development, LLC, the Deerfield Foundation, and a New York City innovation center.[[1]](https://biofuture.com/james-e-flynn/)[[2]](https://www.leadersmag.com/issues/2022.3_Jul/Purpose/LEADERS_James_Flynn_Deerfield.html) Previously, he was a top-ranked analyst at Furman Selz (ING Barings), Vice President of Corporate Development at Alpharma Inc., and a senior analyst at Kidder, Peabody & Co.[[1]](https://biofuture.com/james-e-flynn/)[[3]](https://fintool.com/app/research/funds/hedge-funds/deerfield-management-company-lp-series-c/people/james-flynn)[[5]](https://www.insidermonkey.com/hedge-fund/deerfield+management/408/) Flynn serves as Director by Deputization, 10% Owner at Nuvalent, Inc. (NUVL), holding approximately 17 million shares valued over $1.4 billion as of mid-2025, reflecting Deerfield's significant stake.[[4]](https://www.gurufocus.com/insider/29180/james-e-flynn) He holds a BS in Cellular and Molecular Biology and Economics from the University of Michigan and an MS in Biotechnology from Johns Hopkins University, and serves on boards including Mount Sinai Health System and as Chairman of the New York Academy of Medicine.[[1]](https://biofuture.com/james-e-flynn/)[[2]](https://www.leadersmag.com/issues/2022.3_Jul/Purpose/LEADERS_James_Flynn_Deerfield.html)[[5]](https://www.insidermonkey.com/hedge-fund/deerfield+management/408/)

View full insider profile →

Trade Price

$3.20

Quantity

9,375,000

Total Value

$30,000,000.00

Shares Owned

30,606,974

Trade Date

Thursday, July 31, 2025

206 days ago

SEC Filing Date

Monday, August 4, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Larimar Therapeutics, Inc.

Company Overview

No company information available
View news mentioning LRMR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/104221

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime